[go: up one dir, main page]

TW200612902A - Inhibiting agents for lipase or cholesterol esterase, and absorption suppressing agents for neutral fat, cholesterol, or cholesterol ester - Google Patents

Inhibiting agents for lipase or cholesterol esterase, and absorption suppressing agents for neutral fat, cholesterol, or cholesterol ester

Info

Publication number
TW200612902A
TW200612902A TW094114589A TW94114589A TW200612902A TW 200612902 A TW200612902 A TW 200612902A TW 094114589 A TW094114589 A TW 094114589A TW 94114589 A TW94114589 A TW 94114589A TW 200612902 A TW200612902 A TW 200612902A
Authority
TW
Taiwan
Prior art keywords
cholesterol
lipase
agents
absorption
suppressing
Prior art date
Application number
TW094114589A
Other languages
Chinese (zh)
Inventor
Toshio Hayami
Hideyuki Kishida
Naoki Arai
Shinnichi Yokota
Kazuya Hamada
Original Assignee
Kaneka Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kaneka Corp filed Critical Kaneka Corp
Publication of TW200612902A publication Critical patent/TW200612902A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/48Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/484Glycyrrhiza (licorice)
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23KFODDER
    • A23K20/00Accessory food factors for animal feeding-stuffs
    • A23K20/10Organic substances
    • A23K20/111Aromatic compounds
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23KFODDER
    • A23K50/00Feeding-stuffs specially adapted for particular animals
    • A23K50/30Feeding-stuffs specially adapted for particular animals for swines
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23KFODDER
    • A23K50/00Feeding-stuffs specially adapted for particular animals
    • A23K50/40Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105Plant extracts, their artificial duplicates or their derivatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Polymers & Plastics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Animal Husbandry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)
  • Birds (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Biotechnology (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Feed For Specific Animals (AREA)
  • Fodder In General (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention has found that human and porcine pancreatic lipase and cholesterol esterase inhibitory activities and the like are possessed by a licorice or licorice extract which has been previously taken orally, or are sufficient in meal experience in the form of a medicine, a chinese herbal remedy, a food additive such as sweetener, or a health food product, or by glabridin, glabrol, glabrene, and 4'-O-methylglabridin contained therein. In addition, it has been proved that giving a feed containing any of these materials to experimental animals suppressed their obesity, and produced the increased excretion of neutral fats and cholesterol into feces, thereby suppressing their absorption in the body. This has enabled the supply of compositions for reducing neutral fats or cholesterol absorption, or for suppressing obesity based on lipase and/or cholesterol inhibition, totally different from dietary fiber-containing compositions which have previously been used commonly.
TW094114589A 2004-05-13 2005-05-05 Inhibiting agents for lipase or cholesterol esterase, and absorption suppressing agents for neutral fat, cholesterol, or cholesterol ester TW200612902A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004143210 2004-05-13
JP2004271567 2004-09-17

Publications (1)

Publication Number Publication Date
TW200612902A true TW200612902A (en) 2006-05-01

Family

ID=35393981

Family Applications (1)

Application Number Title Priority Date Filing Date
TW094114589A TW200612902A (en) 2004-05-13 2005-05-05 Inhibiting agents for lipase or cholesterol esterase, and absorption suppressing agents for neutral fat, cholesterol, or cholesterol ester

Country Status (3)

Country Link
JP (1) JPWO2005110400A1 (en)
TW (1) TW200612902A (en)
WO (1) WO2005110400A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109689081A (en) * 2016-08-31 2019-04-26 釜山大学校产学协力团 Localised adiposities therapeutic composition and micropin comprising it
CN115925778A (en) * 2022-12-13 2023-04-07 五邑大学 A kind of glycyrrhetinic acid-dodecane-cholesterol compound and its synthesis method and application

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200808333A (en) * 2006-04-17 2008-02-16 Kaneka Corp Licorice polyphenol preparation
JPWO2008143182A1 (en) * 2007-05-17 2010-08-05 株式会社カネカ Composition containing licorice polyphenol
JP5364580B2 (en) 2007-08-22 2013-12-11 株式会社カネカ Method for producing reduced coenzyme Q10 and method for stabilizing the same
US20100324075A1 (en) * 2007-12-21 2010-12-23 University Of Cincinnati Therapeutic use of carboxyl ester lipase inhibitors
JP2011231057A (en) * 2010-04-28 2011-11-17 Kao Corp Ceramide production enhancer
JP6236697B2 (en) * 2012-12-27 2017-11-29 株式会社ゆふ・は Absorbing material and soap using the same
JP7602854B2 (en) * 2017-08-10 2024-12-19 小林製薬株式会社 Bofutsushosan Extract
JP7535838B2 (en) 2017-08-10 2024-08-19 小林製薬株式会社 Lipid excretion promoter
CN113598253A (en) * 2021-07-14 2021-11-05 云南润攀生物科技有限公司 Ketogenic herbal tea for promoting ketogenic effect and increasing body fat decomposition
CN115736054B (en) * 2022-12-05 2024-09-03 安徽农业大学 Blood glucose-reducing lipid-lowering solid wolfberry flower tea and preparation method thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000226324A (en) * 1998-11-30 2000-08-15 Kansai Koso Kk Liquid agent composition for cleaning/wiping and for cosmetic water
IL138603A0 (en) * 2000-09-21 2001-10-31 Ready Made 37 1999 Ltd Licorice extract for use as a medicament
TWI329516B (en) * 2000-12-12 2010-09-01 Kaneka Corp Composition for preventing or ameliorating multiple risk factor syndromes and visceral fat-type obesity
KR20050035142A (en) * 2001-10-11 2005-04-15 카네카 코포레이션 Peroxisome proliferator activated receptor ligands and process for producing the same
JP4191420B2 (en) * 2002-03-26 2008-12-03 株式会社カネカ Edible oil and fat composition comprising a licorice hydrophobic extract

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109689081A (en) * 2016-08-31 2019-04-26 釜山大学校产学协力团 Localised adiposities therapeutic composition and micropin comprising it
CN109689081B (en) * 2016-08-31 2022-12-16 Sn维亚股份有限公司 Composition for treating local obesity and microneedle comprising same
CN115925778A (en) * 2022-12-13 2023-04-07 五邑大学 A kind of glycyrrhetinic acid-dodecane-cholesterol compound and its synthesis method and application

Also Published As

Publication number Publication date
JPWO2005110400A1 (en) 2008-03-21
WO2005110400A1 (en) 2005-11-24

Similar Documents

Publication Publication Date Title
TW200612902A (en) Inhibiting agents for lipase or cholesterol esterase, and absorption suppressing agents for neutral fat, cholesterol, or cholesterol ester
MX2009007014A (en) Ground meat and meat analog compositions having improved nutritional properties.
DE602007012141D1 (en) FRUIT CHOCOLATE OR SIMILAR
WO2007079443A3 (en) Bioactive complex compositions and methods of use thereof
MXPA04009741A (en) Method and dietary composition for improving fat digestibility.
ATE410076T1 (en) FOOD OR ANIMAL FEED CONTAINING BONE HEALTH SUPPORTING PLANT EXTRACT FROM AMELANCHIER
MX2010003651A (en) Lipid compositions for the treatment of gastro-intestinal disorders and the promotion of intestinal development and maturation.
WO2009010368A3 (en) Composition comprising bacteria and lecithin
WO2005053710A3 (en) Food composition comprising glucosamine
MY145662A (en) Nutrition for obese patients
GB0615781D0 (en) Prebiotic composition
MX2009006342A (en) Nutritional supplement composition for treatment of ocular diseases.
EA201070893A1 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF BONE DISEASES
HK1058459A1 (en) Kernel oil from plant kernel, process for extracting same, pharmaceutical composition and use thereof
WO2006069668A8 (en) Method for producing a raw oil from mixtures of micro-organisms and plants, oil produced according to said method and specific uses of the thus produced oil and, optionally, additional refined oil
WO2006109194A3 (en) Chromium-fatty acid compounds and methods of making and using thereof
CR8265A (en) MILK FRACTIONS AND MILK PREPARATIONS FOR THE TREATMENT AND / OR PREVENTION OF DISEASES MEDIATED BY COX-2
WO2008102017A3 (en) Food comprising polyunsaturated fatty acids for the prevention of chronic diseases
UA88165C2 (en) Use of trisubstituted benzopyranones
PT1596810E (en) Use of banana extract for the treatment of inflammatory bowel disease
MX2007004879A (en) Protection of bioactive food ingredients by means of encapsulation.
EA201301052A1 (en) BIOLOGICALLY ACTIVE ADDITION TO FOOD FOR NORMALIZATION OF THE LEVEL OF MEN ANDROGENS, GENERAL CONDITION, REDUCTION OF OBESITY
MX2010009315A (en) Nutritional compositions for promotion of bone growth and maintenance of bone health comprising extracts of for example rosemary or caraway.
WO2011019210A3 (en) Dietary supplement, feed and pharmaceutical composition containing chia seed and maca, and preparation method thereof
WO2008022807A3 (en) Lipoxin a4 analogs for the treatment and prevention of intestinal fibrosis